<DOC>
	<DOCNO>NCT01388036</DOCNO>
	<brief_summary>Beta 1 Adrenergic antagonist ( beta blocker ) major role treatment CHF , IHD hypertension . However , large interindividual variability response beta blocker . The hypothesis underlie study genetic difference individual determine individual response esmolol , betablocker administer intravenously . Esmolol administer intravenously healthy volunteer , effect heart rate blood pressure monitor . In addition , measure plasma renin activity plasma level norepinephrine .</brief_summary>
	<brief_title>Genetic Determinants Hemodynamic Response Esmolol</brief_title>
	<detailed_description />
	<mesh_term>Bradycardia</mesh_term>
	<mesh_term>Esmolol</mesh_term>
	<criteria>healthy male female able understand sign inform consent consumption medication bradycardia &lt; 50 BPM hypersensitivity beta blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>heart rate</keyword>
</DOC>